VivoSeq
Musculoskeletal

Juvenile Idiopathic Arthritis

59

Pipeline Programs↗

12

Active Trials↗

25

Companies Involved↗

Juvenile Idiopathic Arthritis is a moderately active landscape with 59 programs across 25 companies. The most active players are Gilead, Italfarmaco, Hope Biosciences Research Foundation. 19 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

22/100

Mech. Concentration

15/100

Completion Rate

77/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 1Italfarmaco logo

Italfarmaco

1 program

Phase 2H

Hope Biosciences Research Foundation

1 program

Phase 2Otsuka logo

Otsuka

1 program

Phase 2K

Kiniksa Pharmaceuticals (UK), Ltd.

1 program

Phase 2UCB logo

UCB

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

46 of 65 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody1320%Protein / enzyme35%Vaccine23%Cell therapy12%

Small molecule leads; the ring shows all 65 classified programs, each share of the total. Modality classified for 100% of 69 pipeline programs.

Analysis

Trial Status

58

clinical trials

Completed33 · 57%
Terminated9 · 16%
Recruiting6 · 10%
Not yet recruiting3 · 5%
Unknown status3 · 5%
Active, not recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

58 trials

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
Recruiting·Pfizer logoPfizer·N/A·NCT05754710·10 enrolled
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Recruiting·—·Phase 3·NCT06654882·400 enrolled
Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT05534347·300 enrolled
Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
Recruiting·OOslo University Hospital·Phase 4·NCT06653634·150 enrolled
The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile Idiopathic Arthritis
Recruiting·SSohag University·Phase 3·NCT06463379·215 enrolled
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT03773965·190 enrolled
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis
Active, not recruiting·AbbVie logoAbbVie·Phase 1·NCT03725007·124 enrolled
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT04527380·101 enrolled
Articular Damage in Patients With Juvenile Idiopathic Arthritis After Transition to Adult Care
Not yet recruiting·IIRCCS Burlo Garofolo·N/A·NCT06895278·100 enrolled
Tofacitinib in Juvenile Idiopathic Arthritis
Not yet recruiting·CConsorci Sanitari de l'Alt Penedès i Garraf·N/A·NCT07211932·58 enrolled
Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
Not yet recruiting·—·Approved·NCT07699107·160 enrolled
Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
Enrolling by invitation·UUniversity of Child Health Sciences and Children's Hospital, Lahore·Phase 3·NCT07386587·60 enrolled
The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary
Completed·UUniversity of Pecs·Phase 1·NCT03833271·62 enrolled
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Completed·Sanofi logoSanofi·Phase 2·NCT02776735·102 enrolled
Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
Completed·MMedical University of Graz·N/A·NCT04200833·10 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)